This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Preliminary Efficacy of the Treatment of Kidney Allografts With Curcumin-containing Preservation Solution

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2011 by Helsinki University Central Hospital.
Recruitment status was:  Recruiting
Helsinki University
Academy of Finland
Information provided by:
Helsinki University Central Hospital Identifier:
First received: January 26, 2011
Last updated: NA
Last verified: January 2011
History: No changes posted
The safety and preliminary efficacy of the addition of an aqueous curcumin-cyclodextrin complex (CDC) solution to graft perfusion solution is studied. CDC has proved safe and highly effective in preventing primary graft non-function, delayed graft function and chronic dysfunction in pre-clinical kidney transplantation animal models. The hypothesis is that addition of CDC to the graft perfusion solution will decrease the incidence of delayed graft function in human kidney transplantation subjects.

Condition Intervention Phase
End Stage Renal Failure With Renal Transplant Device: CDC solution Device: UW-solution Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by Helsinki University Central Hospital:

Primary Outcome Measures:
  • Delayed Graft Function [ Time Frame: 7 days ]

Secondary Outcome Measures:
  • Primary non-function [ Time Frame: 1 year ]
  • Acute rejection [ Time Frame: 1 year ]
  • Graft function eGFR [ Time Frame: 30 days, 90 days ]
  • Graft Survival [ Time Frame: 1 year ]
  • Patient Survival [ Time Frame: 1 year ]
  • Length of stay in hospital [ Time Frame: upto 1 year ]

Estimated Enrollment: 20
Study Start Date: January 2011
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: CDC graft perfusion
Flushing of kidney allografts prior to transplantation with UW-solution containing CDC
Device: CDC solution
2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation
Other Name: Curcumin-cyclodextrin
Sham Comparator: Sham perfusion Device: UW-solution
500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
Other Name: Viaspan


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with ESRD assigned for kidney transplantation, written informed consent

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01285375

Contact: Jakob Stenman, MD, PhD +35894711

Helsinki University Central Hospital Recruiting
Helsinki, Finland, 00029-HUS
Principal Investigator: Kaija Salmela, Docent         
Sub-Investigator: Jakob Stenman, MD, PhD         
Sub-Investigator: Marko Lempinen, MD, PhD         
Sub-Investigator: Lauri Kyllönen, Docent         
Sponsors and Collaborators
Helsinki University Central Hospital
Helsinki University
Academy of Finland
Principal Investigator: Kaija Salmela, Docent Head of Kidney Transplantation Unit
  More Information

Responsible Party: Kaija Salmela, MD, Head of Kidney Transplantation Unit, Department of Liver and Transplantation Surgery Identifier: NCT01285375     History of Changes
Other Study ID Numbers: 236153
236153 ( Registry Identifier: Hospital District of Helsinki and Uusimaa )
Study First Received: January 26, 2011
Last Updated: January 26, 2011

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Kidney Diseases
Urologic Diseases
Pharmaceutical Solutions
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017